MM_Hub: We recently summarized the outcomes of the BCMA-#CARTcell ide-cel in patients who had received at least 3 prior lines of therapy. At #ASCO21, @ldandersonjr presents the KarMMa trial with longer follow-up and OS results in important subgroups #mmsm 👇

by | Jun 10, 2021 | Twitter

We recently summarized the outcomes of the BCMA-#CARTcell ide-cel in patients who had received at least 3 prior lines of therapy. At #ASCO21, @ldandersonjr presents the KarMMa trial with longer follow-up and OS results in important subgroups #mmsm...

SLentzsch: Some of the data presented today @ASCO will shape the future treatment of Myeloma! Will this GPRC5D TCE the rescue after BCMA treatment in #Myeloma? Congrats @BerdejaJesus on a great presentation 👏

by | Jun 10, 2021 | Twitter

Some of the data presented today @ASCO will shape the future treatment of Myeloma! Will this GPRC5D TCE the rescue after BCMA treatment in #Myeloma? Congrats @BerdejaJesus on a great presentation 👏 https://t.co/i1mKY03EJS— Suzanne Lentzsch, MD, PhD (@SLentzsch) June...